Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

Immuneering (IMRX) EBITDA: 2020-2023

Historic EBITDA for Immuneering (IMRX) over the last 4 years, with Dec 2023 value amounting to -$53.4 million.

  • Immuneering's EBITDA fell 14.90% to -$15.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$53.4 million, marking a year-over-year decrease of 5.84%. This contributed to the annual value of -$53.4 million for FY2023, which is 5.84% down from last year.
  • According to the latest figures from FY2023, Immuneering's EBITDA is -$53.4 million, which was down 5.84% from -$50.5 million recorded in FY2022.
  • In the past 5 years, Immuneering's EBITDA ranged from a high of -$17.0 million in FY2020 and a low of -$53.4 million during FY2023.
  • In the last 3 years, Immuneering's EBITDA had a median value of -$50.5 million in 2022 and averaged -$45.8 million.
  • Data for Immuneering's EBITDA shows a maximum YoY slumped of 97.09% (in 2021) over the last 5 years.
  • Over the past 4 years, Immuneering's EBITDA (Yearly) stood at -$17.0 million in 2020, then crashed by 97.09% to -$33.6 million in 2021, then slumped by 50.35% to -$50.5 million in 2022, then declined by 5.84% to -$53.4 million in 2023.